Discussing four papers that caught our eyes from the last few weeks:
Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage.
ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544
Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795
An RNA assay to predict gemcitabine sensitivity: https://doi.org/10.1200/JCO.22.02668
Management of skin cancers with ICIs in kidney transplant patients: https://doi.org/10.1200/JCO.23.02570
